Johnson & Johnson receives positive CHMP opinion for
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of...
Source: globenewswire.com
📰 Antitumor Activity News
Antitumor Activity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Antitumor Activity. Real-time updates on events, politics, business and more.
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA&#x...
Source: yahoo.com
Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST
News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...
Region Flamande United States Catherine Taylor Kiran Patel Zayn Qureshi Janssen Research Development
Source: marketscreener.com
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and...
Source: marketscreener.com
Landmark Phase 3 MARIPOSA Study Shows
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in...
Source: globenewswire.com
New Long-Term Data from the CHRYSALIS Study Show Median
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...
Source: globenewswire.com
BDC-1001 With or Without Nivolumab Shows Early Signs of Clinical Activity, Tolerability in HER2-Expressing Solid Tumors
BDC-1001 monotherapy and in combination with nivolumab generated antitumor activity with acceptable tolerability in patients with advanced HER2-expressing solid tumors, according to topline data from the dose-escalation portion of a phase 1 trial.
United States Editha Perez Bdc 1001 Monotherapy Antitumor Activity Advanced Her2 Expressing Solid Tumors Dose Escalation Portion Ofa Phase 1 Trial
Source: onclive.com
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial... | January 9, 2023
United States John Park Peter Luo Adagene Inc Macquarie University Drug Administration Project Optimu
Source: marketscreener.com
Ryvu Therapeutics Presents Clinical and Translational Data
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with...
United States New Orleans Tomasz Rzymski Hendrik Nogai Camille Abboud American Society Of Hematology
Source: globenewswire.com
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com